BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zai K, Hirota M, Yamada T, Ishihara N, Mori T, Kishimura A, Suzuki K, Hase K, Katayama Y. Therapeutic effect of vitamin D3-containing nanostructured lipid carriers on inflammatory bowel disease. J Control Release 2018;286:94-102. [PMID: 30017723 DOI: 10.1016/j.jconrel.2018.07.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Tang C, Chen H, Dong J. Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) as Food-Grade Nanovehicles for Hydrophobic Nutraceuticals or Bioactives. Applied Sciences 2023;13:1726. [DOI: 10.3390/app13031726] [Reference Citation Analysis]
2 Aman Mohammadi M, Farshi P, Ahmadi P, Ahmadi A, Yousefi M, Ghorbani M, Hosseini SM. Encapsulation of Vitamins Using Nanoliposome: Recent Advances and Perspectives. Adv Pharm Bull 2023;13:48-68. [PMID: 36721823 DOI: 10.34172/apb.2023.005] [Reference Citation Analysis]
3 Santos FH, Panda SK, Ferreira DCM, Dey G, Molina G, Pelissari FM. Targeting infections and inflammation through micro and nano-nutraceuticals. Food Bioscience 2022;49:101891. [DOI: 10.1016/j.fbio.2022.101891] [Reference Citation Analysis]
4 Xu C, Chen S, Chen C, Ming Y, Du J, Mu J, Luo F, Huang D, Wang N, Lin Z, Weng Z. Colon-targeted oral nanoparticles based on ROS-scavenging hydroxyethyl starch-curcumin conjugates for efficient inflammatory bowel disease therapy. Int J Pharm 2022;623:121884. [PMID: 35661797 DOI: 10.1016/j.ijpharm.2022.121884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wu Z, Liu D, Deng F. The Role of Vitamin D in Immune System and Inflammatory Bowel Disease. JIR 2022;Volume 15:3167-85. [DOI: 10.2147/jir.s363840] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Li L, Cheng L, Li Z, Li C, Hong Y, Gu Z. Butyrylated starch protects mice from DSS-induced colitis: combined effects of butyrate release and prebiotic supply. Food Funct 2021;12:11290-302. [PMID: 34635904 DOI: 10.1039/d1fo01913a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Xu Y, Michalowski CB, Beloqui A. Advances in lipid carriers for drug delivery to the gastrointestinal tract. Current Opinion in Colloid & Interface Science 2021;52:101414. [DOI: 10.1016/j.cocis.2020.101414] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
8 Mu Y, Kinashi Y, Li J, Yoshikawa T, Kishimura A, Tanaka M, Matsui T, Mori T, Hase K, Katayama Y. Polyvinyl Butyrate Nanoparticles as Butyrate Donors for Colitis Treatment. ACS Appl Bio Mater 2021;4:2335-2341. [DOI: 10.1021/acsabm.0c01105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mishra RK, Ahmad A, Kumar A, Vyawahare A, Raza SS, Khan R. Lipid-based nanocarrier-mediated targeted delivery of celecoxib attenuate severity of ulcerative colitis. Materials Science and Engineering: C 2020;116:111103. [DOI: 10.1016/j.msec.2020.111103] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
10 Mu Y, Kinashi Y, Kishimura A, Mori T, Hase K, Katayama Y. Effect of polyvinyl butyrate nanoparticles incorporated with immune suppressing vitamins on alteration of population of intestinal immune cells. Progress in Natural Science: Materials International 2020;30:707-710. [DOI: 10.1016/j.pnsc.2020.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Huguet-Casquero A, Xu Y, Gainza E, Pedraz JL, Beloqui A. Oral delivery of oleuropein-loaded lipid nanocarriers alleviates inflammation and oxidative stress in acute colitis. Int J Pharm 2020;586:119515. [PMID: 32544520 DOI: 10.1016/j.ijpharm.2020.119515] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
12 Chaubey P, Momin M, Sawarkar S. Significance of Ligand-Anchored Polymers for Drug Targeting in the Treatment of Colonic Disorders. Front Pharmacol 2019;10:1628. [PMID: 32161536 DOI: 10.3389/fphar.2019.01628] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Leskovar D, Meštrović T, Barešić A, Kraljević I, Panek M, Čipčić Paljetak H, Perić M, Matijašić M, Rogić D, Barišić A, Ljubas Kelečić D, Vranešić Bender D, Krznarić Ž, Verbanac D. The Role of Vitamin D in Inflammatory Bowel Disease - Assessing Therapeutic and Preventive Potential of Supplementation and Food Fortification. Food Technol Biotechnol 2018;56:455-63. [PMID: 30923443 DOI: 10.17113/ftb.] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Zhu X, Zhu Y, Li C, Yu J, Ren D, Qiu S, Nie Y, Yu X, Xu X, Zhu W. 1,25‑Dihydroxyvitamin D regulates macrophage polarization and ameliorates experimental inflammatory bowel disease by suppressing miR-125b. International Immunopharmacology 2019;67:106-18. [DOI: 10.1016/j.intimp.2018.12.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
15 Garg M, Royce SG, Tikellis C, Shallue C, Sluka P, Wardan H, Hosking P, Monagle S, Thomas M, Lubel JS, Gibson PR. The intestinal vitamin D receptor in inflammatory bowel disease: inverse correlation with inflammation but no relationship with circulating vitamin D status. Therap Adv Gastroenterol 2019;12:1756284818822566. [PMID: 30719077 DOI: 10.1177/1756284818822566] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]